Table S1. Further hospitalizations during the 6 months after hospitalization in HZ cohort and non-HZ cohort, period 2015-2017.

| Major Diagnostic Category | HZ cohort (%), 95%CI | Non-HZ cohort (%), 95%CI | Relative risk RR (95% CI) | p value |
|---------------------------|-----------------------|---------------------------|--------------------------|---------|
| 01 - Diseases and Disorders of the Nervous System | 5.56 (3.25; 7.86) | 4.24 (3.32; 5.16) | 1.31 (0.82; 2.10) | 0.281 |
| 02 - Diseases and Disorders of the Eye | 1.59 (0.33; 2.85) | 0.54 (0.21; 0.88) | 2.92 (1.07; 7.99) | 0.031 |
| 03 - Diseases and Disorders of the Ear, Nose, Mouth And Throat | 0.00 (0.0; 0.0) | 0.16 (-0.02; 0.35) | - | 0.433 |
| 04 - Diseases and Disorders of the Respiratory System | 6.08 (3.67; 8.49) | 4.35 (3.41; 5.28) | 1.40 (0.89; 2.20) | 0.165 |
| 05 - Diseases and Disorders of the Circulatory System | 3.97 (2.00; 5.94) | 7.28 (6.09; 8.47) | 0.55 (0.32; 0.92) | 0.027 |
| 06 - Diseases and Disorders of the Digestive System | 4.23 (2.20; 6.26) | 4.67 (3.71; 5.64) | 0.91 (0.54; 1.53) | 0.723 |
| 07 - Diseases and Disorders of the Hepatobiliary System And Pancreas | 1.59 (0.33; 2.85) | 2.12 (1.46; 2.78) | 0.75 (0.32; 1.76) | 0.512 |
| 08 - Diseases and Disorders of the Musculoskeletal System And Connective Tissue | 4.50 (2.41; 6.59) | 6.63 (5.49; 7.76) | 0.68 (0.41; 1.11) | 0.141 |
| 09 - Diseases and Disorders of the Skin, Subcutaneous Tissue And Breast | 1.32 (0.17; 2.47) | 1.47 (0.92; 2.02) | 0.90 (0.35; 2.33) | 0.833 |
| 10 - Diseases and Disorders of the Endocrine, Nutritional And Metabolic System | 0.53 (-0.20; 1.26) | 0.49 (0.17; 0.81) | 1.08 (0.24; 4.99) | 0.919 |
| 11 - Diseases and Disorders of the Kidney And Urinary Tract | 3.17 (1.41; 4.94) | 4.24 (3.32; 5.16) | 0.75 (0.41; 1.36) | 0.358 |
| 12 - Diseases and Disorders of the Male Reproductive System | 0.26 (-0.25; 0.78) | 0.38 (0.10; 0.66) | 0.70 (0.09; 5.64) | 0.733 |
| 13 - Diseases and Disorders of the Female Reproductive System | 0.00 (0.0; 0.0) | 0.38 (0.10; 0.66) | - | 0.231 |
| 14 - Pregnancy, Childbirth And Puerperium | 0.00 (0.0; 0.0) | 0.00 (0.0; 0.0) | - | - |
| 15 - Newborn And Other Neonates (Perinatal Period) | 0.00 (0.0; 0.0) | 0.00 (0.0; 0.0) | - | - |
| 16 - Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders | 1.85 (0.49; 3.21) | 1.58 (1.01; 2.14) | 1.18 (0.52; 2.66) | 0.703 |
| 17 - Myeloproliferative Disorders (Poorly Differentiated Neoplasms) | 4.76 (2.62; 6.91) | 6.63 (5.49; 7.76) | 0.72 (0.44; 1.16) | 0.199 |
| 18 - Infectious and Parasitic Disorders (Systemic or unspecified sites) | 3.97 (2.00; 5.94) | 2.01 (1.37; 2.65) | 1.97 (1.09; 3.56) | 0.026 |
| 19 - Mental Diseases and Disorders | 0.00 (0.0; 0.0) | 0.43 (0.13; 0.74) | - | 0.200 |
| 20 - Alcohol/Drug Use or Induced Mental Disorders | 0.00 (0.0; 0.0) | 0.05 (-0.05; 0.16) | - | 0.650 |
| 21 - Injuries, Poison And Toxic Effect of Drugs | 0.79 (-0.10; 1.69) | 0.33 (0.07; 0.59) | 2.44 (0.61; 9.69) | 0.195 |
| 22 - Burns | 0.00 (0.0; 0.0) | 0.00 (0.0; 0.0) | - | - |
| 23 - Factors Influencing Health Status and Other Contacts with Health Services | 1.06 (0.03; 2.09) | 1.58 (1.01; 2.14) | 0.67 (0.24; 1.90) | 0.455 |
| 24 - Multiple Significant Trauma | 0.00 (0.0; 0.0) | 0.11 (-0.04; 0.26) | - | 0.522 |
| 25 - Human Immunodeficiency Virus Infection | 1.06 (0.03; 2.09) | 0.00 (0.0; 0.0) | - | <0.001 |
| MDC Category Missing | 0.00 (0.0; 0.0) | 0.33 (0.07; 0.59) | - | 0.267 |
| Pre-MDC | 0.00 (0.0; 0.0) | 0.16 (-0.02; 0.35) | - | 0.433 |
Table S2. Days of drug therapy in the 6-months after and before hospitalization in HZ cohort and non-HZ cohort, period 2015-2017.

| ATC codes | Pre-H HZ cohort (median, IQR) | Pre-H non-HZ cohort (median, IQR) | p value pre-H | Post-H HZ cohort (median, IQR) | Post-H non-HZ cohort (median, IQR) | p value post-H | p value post- vs pre-H in HZ and non-HZ |
|-----------|-------------------------------|----------------------------------|--------------|-------------------------------|-----------------------------------|--------------|-------------------------------------|
| A-Antimicrobial agents |                               |                                  |              |                               |                                   |              |                                     |
| B-Blood and blood forming organs |                               |                                  |              |                               |                                   |              |                                     |
| C-Cardiovascular system |                               |                                  |              |                               |                                   |              |                                     |
| D-Dermatologicals |                               |                                  |              |                               |                                   |              |                                     |
| G-Genito-urinary system and sex hormones |                               |                                  |              |                               |                                   |              |                                     |
| H-Systemic hormonal preparations excluding sex hormones and insulin | 67.67 (26.7-139.6) | 64 (30-125) | 0.488 | 67 (30-133) | 60 (25-125) | 0.532 | 0.748 |
| J-Anti-infectives for systemic use |                               |                                  |              |                               |                                   |              |                                     |
| J05AB11-Valaciclovir | 7 (7-11) | 11 (7-23) | 0.035 | 7 (7-7) | 7 (7-6) | 0.876 | 0.029 |
| J05AB09-Famiclovir | 14 (7-14) | 7 (7-7) | 0.553 | 14 (7-14) | 10 (6-14) | 0.317 | 0.005 |
| J05AB01-Aciclovir | 7 (6-7) | 7 (5-14) | 0.423 | 7 (7-7) | 7 (5-14) | 0.876 | 0.029 |
| J05AB15-Brivudine | 7 (7-7) | 7 (7-7) | 0.263 | 7 (7-7) | 7 (7-7) | 0.507 | <0.001 |
| K-Antineoplastic and immunomodulating agents | 29 (6-115) | 72.24 (16.7-180) | 0.006 | 59 (25-163) | 90 (24-180) | 0.158 | 0.004 |
| M-Musculo-skeletal system |                               |                                  |              |                               |                                   |              |                                     |
| N-Nervous system |                               |                                  |              |                               |                                   |              |                                     |
| N03AX16-Pregabalin | 14 (4-39) | 28 (11-63) | 0.002 | 25 (8-49) | 18 (9-44) | 0.684 | <0.001 |
| N03AX12-Gabapentin | 17 (8-66) | 26 (8-49) | 0.338 | 25 (8-44) | 25 (8-42) | 0.921 | <0.001 |
| N06AA09-Amitriptyline | 11 (11-43) | 21.34 (11-43) | 0.298 | 21 (11-43) | 21 (11-43) | 0.654 | 0.00 |
| N01BB02-Lidocaine | 7 (4-18) | 7 (4-12) | 0.907 | 9 (4-22) | 4 (4-7) | 0.071 | <0.001 |
| N02BE-Anilides | 11 (5-21) | 11 (5-21) | 0.823 | 11 (11-21) | 11 (5-21) | 0.414 | 0.582 |
| N02A-Opioids | 11 (5-46) | 13 (5-43) | 0.301 | 16 (6-52) | 11 (5-36) | <0.001 | 0.003 |
| P-Antiparasitic products. insecticides and repellents | 7 (3-12) | 5 (3-47) | 0.957 | 12 (5-47) | 5 (3-13.32) | 0.198 | 0.353 |
| R-Respiratory system |                               |                                  |              |                               |                                   |              |                                     |
| S-Sensory organs |                               |                                  |              |                               |                                   |              |                                     |
| V-Various | 0 (0-10) | 0 (0-19) | 0.640 | 1 (0-9) | 0 (0-12) | 0.524 | 0.842 |
| Not specified | 0 (0-0) | 0 (0-0) | - | 0 (0-0) | 0 (0-0) | - | 1.000 |